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ABSTRACT
Background: The outbreak of Zika virus (ZIKV) infection in Brazil has raised concerns that 
infection during pregnancy could cause microcephaly and other severe neurodevelopmental 
malformations in the fetus. The mechanisms by which ZIKV causes fetal abnormalities are largely 
unknown. The importance of pre-infection with dengue virus (DENV), or other flaviviruses en-
demic to Brazil, remains to be investigated. It has been reported that antibodies directed against 
DENV can increase ZIKV infectivity by antibody dependent enhancement (ADE), suggesting 
that a history of prior DENV infection might worsen the outcome of ZIKV infection.
Methods: We used bioinformatics tools to design 18 peptides from the ZIKV envelope containing 
predicted HLA-I T-cell epitopes and investigated T-cell cross-reactivity between ZIKV-infected 
individuals and DENV-vaccinated subjects by IFNγ ELISPOT. 
Results: Three peptides induced IFNγ production in both ZIKV-infected subjects and in 
DENV-vaccinated individuals. Flow cytometry indicated that 1 ZIKV peptide induced a CD4+ 
T-cell response in DENV-vaccinated subjects.
Conclusions: We demonstrated that vaccination against DENV induced a T-cell response against 
ZIKV and identified one such CD4+ T-cell epitope. The ZIKV-reactive CD4+ T cells induced by 
DENV vaccination and identified in this study could contribute to the appearance of cross-reac-
tive antibodies mediating ADE.
Keywords: zika virus, dengue virus, T cell, IFNγ, ELISPOT, CD4, antibody dependent enhance-
ment.
LIST OF ABBREVIATIONS
ZIKV: Zika virus  
YF: Yellow Fever 
DENV: Dengue virus 
ADE: Antibody dependent enhancement 
OAS: Original antigenic sin 
nd: Not done 
na: Not applicable 
unk: Unknown
INTRODUCTION
Zika virus (ZIKV) infection was first identified in the Ziika forest of Uganda in 1947 [1]. This vi-
rus is a member of the Flaviviridae, a family of viruses that also includes Yellow Fever (YF), West 
Nile, and Dengue viruses (DENV), and ZIKV can be transmitted via mosquito bites, through 
sexual contact or blood transfusions, or from an infected pregnant woman to her developing 
fetus. Until recently, ZIKV was understudied because the infection was thought to be associated 
only with a mild viral illness of limited duration. It is estimated that only 20% of infected humans 
show signs of ZIKV infection during the acute phase, with symptoms including skin rash, head-
ache, asthenia, and conjunctivitis. In 2014, the virus suddenly expanded its range dramatically 
and appeared in the Americas, leading to the most widespread ZIKV outbreak recorded. The 
recent epidemic of ZIKV in Brazil has raised concerns that ZIKV infection during pregnancy 
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could cause severe neurodevelopmental malformations in the fetus, including microcephaly [2, 
3]. Evidence includes epidemiological studies showing a strong temporal and geographical asso-
ciation between ZIKV and microcephaly[4], detection of ZIKV in the brain of infants born with 
microcephaly [3, 5, 6], and ZIKV neurological damage in animal models [7-9]. Three different 
studies performed in French Polynesia (retrospective), Rio de Janeiro, and Bahia have estimated 
the risk of microcephaly to be between 0.95% and 29% for pregnant women infected with ZIKV 
[10-13]. A more recent study in the United States estimated the risk to be 6%, with an increased 
vulnerability if ZIKV infection occurred during the first trimester [14]. A temporal association 
between an increase in the incidence of microcephaly cases and ZIKV infection was also noted in 
Colombia [15]. The mechanisms by which ZIKV causes fetal abnormalities are largely unknown. 
In fact, we still do not know the risk factors associated with fetal microcephaly among pregnant 
women.
The importance of pre-infection with DENV, another flavivirus endemic to Brazil, remains to be 
investigated. It has been reported that antibodies directed against DENV can increase ZIKV in-
fectivity in vitro by antibody dependent enhancement (ADE) [16-19], suggesting that a history of 
prior DENV infection might worsen the outcome of a subsequent ZIKV infection. However, the 
clinical relevance of ADE to ZIKV pathology remains to be determined [20]. Several studies have 
suggested the possible involvement of cross-reactive T-cell epitopes in DENV pathogenesis. More 
specifically, memory T-cell clones generated during primary dengue infection in response to epi-
topes from 1 dengue serotype can cross-react with epitope variants presented during a subsequent 
infection with a different dengue serotype. We have previously shown differential serotype-specif-
ic CD8+ T-cell immunogenicity of DENV proteins [21]. In mice previously infected with DENV, 
the CD8 T-cell response to ZIKV infection was almost exclusively driven by a limited number of 
ZIKV/DENV cross-reactive memory cells [22]. To date, no ZIKV or ZIKV/DENV cross-reactive 
epitopes have been identified in humans.  Here, we hypothesized that prior DENV vaccination 
impacts immunity to ZIKV through T-cell cross-reactivity.
In this study, we investigated virus specific T-cell cross-reactivity between ZIKV and DENV. 
We selected 18 peptides from the ZIKV envelope with predicted epitopes for the most common 
HLA-I alleles in Brazil, based on their sequence similarity/dissimilarity with DENV. We identified 
3 peptides that induced an IFNγ response in ZIKV-infected patients and in DENV-vaccinated 
individuals. One of these peptides was found to be a CD4+ T-cell epitope.
MATERIALS AND METHODS
Human participants
We selected 7 ZIKV-infected and 9 DENV-vaccinated individuals from São Paulo, Brazil. All 
participants were enrolled after signing a written consent form approved by the University of São 
Paulo’s Institutional Review Board (CAPPesq 0652/09 and 553/08, respectively). Samples from 
the DENV-vaccinated individuals were collected between January and August 2014 before the 
ZIKV outbreak reached São Paulo and selected based on the expression of at least 1 allele of the 
following HLA-I: HLA-A2, HLA-A24, and HLA-B44. Of the ZIKV-infected patients, 2 reported 
previous DENV infection (801 and 533). None of the DENV-vaccinated individuals reported pre-
vious DENV infection. Blood from control subjects was obtained from the New York Blood Bank. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient sedimentation us-
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ing Ficoll-Paque (Lymphoprep, Nycomed Pharma, Oslo, Norway). Isolated PBMCs were washed 
twice in Hank’s balanced salt solution (Gibco, Grand Island, NY) and cryopreserved in RPMI 
1640 (Gibco), supplemented with 20% heat-inactivated fetal bovine serum (FBS; Hyclone Lab-
oratories, Logan UT), 50 U/ml of penicillin (Gibco), 50 µg/ml of streptomycin (Gibco), 10mM 
glutamine (Gibco) and 10% dimethylsulfoxide (DMSO; Sigma, St Louis, MO). Cryopreserved 
cells from all participants were stored in liquid nitrogen until used in the assays.
DNA extraction and HLA typing
DNA was extracted from peripheral blood using Qiagen kits (QIAamp DNA Mini Kit, Qiagen, 
Inc, Valencia, CA). The HLA A, B, C and DRB1 typing was performed using PCR and amplifi-
cation using Sequence-Specific Oligonucleotide (SSP) contained in LABType kits (One Lambda, 
Inc, Canoga Park, CA).
Epitope prediction and sequence alignment
The HLA-I epitope predictions were made using Net CTL 1.2 [23] (with a prediction score 
threshold for epitope identification of 0.75), and HLA-II binding predictions were made using 
the IEDB analysis resource consensus tool [24, 25]. Amino acid sequences were aligned using the 
EMBL-EBI bioinformatics framework [26, 27]. Sequence data from Zika MR766 (NCBI Refer-
ence Sequence: YP_002790881.1), DENV-1 (UniProtKB/Swiss-Prot: Q1L6I3), DENV-2 (Uni-
ProtKB/Swiss-Prot: B8QED9), DENV-3 (UniProtKB/Swiss-Prot: Q2YH64), and DENV-4 (Uni-
ProtKB/Swiss-Prot: Q5UU53) were used.
ELISPOT
Cryopreserved PBMC specimens were thawed, washed, and the cell viability was assessed using 
the Countess Automated Cell Counter system (Invitrogen, Carlsbad, CA). IFNγ ELISPOT assays 
were conducted following the manufacturer’s instructions (Mabtech, Cincinnati, OH). The ZIKV 
peptides (GenScript, Piscataway, NJ) were reconstituted with DMSO or water at a concentration 
of 1 mg/ml and used at a final concentration of 10 μg/mL in duplicate. The PBMCs were plated at 
a concentration of 1 × 105 cells per well. Spots were counted using AID EliSpot Reader software 
v6.0. Results from unstimulated PBMCs were used to determine the background level of IFNγ 
production and multiplied by 2 for each donor individually.
Flow cytometry and monoclonal antibodies
Freshly thawed PBMCs were labeled with CellTrace Violet (Invitrogen) following the manufac-
turer’s instructions and cultured for 6 days at 37°C and 5% CO2 in RPMI medium supplemented 
with 10% fetal bovine serum (FBS) and 20 units/ml of IL-2 (Sigma), in the presence or absence of 
10 μg/ml of peptide. The PBMCs were then re-stimulated with peptide in the presence of mo-
nensin (Golgi Stop, BD Biosciences, San Jose, CA) for 12 hours. Cells were washed and stained 
in Brilliant Violet Stain Buffer (BD Biosciences) at room temperature for 15 minutes in 96-well 
V-bottom plates in the dark. Samples were then washed and fixed using Cytofix/Cytoperm (BD 
Biosciences) before flow cytometry analysis. Intracellular staining was performed in Perm/Wash 
(BD Biosciences), and the following mAbs were used, CD3 PerCP-Cy5.5 (clone UCHT1), CD4 
BV605 (clone RPA-T4), CD8 BV711 (clone RPA-T8), and IFNγ APC (clone B27), all from BD 
Biosciences. Live/dead Fixable Violet Cell Stain was from Life Technologies (Eugene, OR). All 
data was acquired on a BD LSRFortessa X-20 instrument (BD Biosciences) and analyzed using 
FlowJo Version 9.9.4 software (TreeStar, Ashland, OR). 
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RESULTS AND DISCUSSION
First, we used Net CTL 1.2 [23] with a threshold of 0.75 to predict the HLA-I epitopes from 
the ZIKV envelope for 3 of the most common alleles in Brazil (HLA-A2 approximately 25%, 
HLA-A24 approximately 10%, and HLA-B44 approximately 11%) [28, 29]. We identified between 
9 and 11 partially overlapping 9-mers for each allele (Table 1). We then proceeded to map these 
epitopes on an alignment of the ZIKV envelope with the envelopes of DENV 1-4 in UniProt [30]. 
Based on the similarity of the Net CTL-predicted epitopes between these viruses, we designed 18 
peptides (17 peptides were 15-mers and one was a 16-mer) containing at least 1 predicted epitope 
each (Table 2). Some of the ZIKV peptides had a high similarity with all DENV serotypes (pep-
tides 1, 2, 4, 9, 10, and 14), and some others had a much lower similarity (peptides 3, 16, 17, and 
18) (Figure 1).
Figure 1. Alignment of ZIKV and DENV Sequences. The ZIKV amino acid sequences of selected pep-
tides were aligned to the corresponding DENV-1, DENV-2, DENV-3, and DENV-4 sequences using EM-
BL-EBI bioinformatics framework. *  indicates positions with a single, fully conserved residue; :  indicates 
conservation between groups of strongly similar properties—roughly equivalent to scoring > 0.5 in the 
Gonnet PAM 250 matrix; . indicates conservation between groups of weakly similar properties—roughly 
equivalent to scoring ≤ 0.5 and > 0 in the Gonnet PAM 250 matrix.
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Table 1. NetCTL Predicted Epitopes
  peptide sequence Predicted HLA-I binding affinity C terminal cleavage affinity TAP transport efficiency Prediction score
HLA-A2 VMAQDKPTV 0.6314 0.7253 0.5250 1.0763
  GLFGKGSLV 0.5499 0.9620 0.2600 0.9770
  TMNNKHWLV 0.6882 0.9214 0.3690 1.1826
  RLKGVSYSL 0.4368 0.9783 1.2640 0.8611
  QMAVDMQTL 0.4571 0.7170 1.1530 0.8466
  RLITANPVI 0.6463 0.8378 0.8370 1.1310
  SLGKGIHQI 0.5049 0.9345 0.5850 0.9220
  GMSWFSQIL 0.5587 0.9007 0.8630 1.0111
  QILIGTLLV 0.5145 0.9302 0.5280 0.9328
  ALGGVMIFL 0.6719 0.8577 1.0030 1.1805
  VMIFLSTAV 0.7082 0.9511 0.5370 1.2252
HLA-A24 QYVCKRTLV 0.2878 0.8548 0.6800 0.7752
  GWGNGCGLF 0.2630 0.4394 2.5710 0.7544
  HWLVHKEWF 0.4919 0.0586 2.8090 1.1966
  WFHDIPLPW 0.3512 0.7479 0.8880 0.9376
  SYSLCTAAF 0.7168 0.8959 2.8950 1.8055
  SLCTAAFTF 0.3226 0.8830 2.5640 0.9477
  PFGDSYIVI 0.3516 0.3935 -0.0860 0.8034
  HWHRSGSTI 0.5154 0.6547 0.6970 1.2305
  DFGSVGGV 0.3936 0.4993 2.1670 1.0215
HLA-B44 LEHGGCVTV 0.5892 0.9765 0.2600 1.6195
  PENLEYRIM 0.3196 0.2960 -0.4540 0.8138
  LEYRIMLSV 0.5119 0.9701 0.5110 1.4396
  DEDRAKVEV 0.2847 0.7879 -0.3030 0.8086
  CEPRTGLDF 0.2820 0.1832 2.2040 0.8364
  LDFSDLYYL 0.2548 0.7789 0.7330 0.7849
  KEWFHDIPL 0.7230 0.8664 1.0750 1.9754
  QEGAVHTAL 0.6119 0.9682 0.7230 1.6977
  SQILIGTLL 0.3871 0.4819 1.0470 1.0839
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Table 2. Selected ZIKV Peptides 
Peptide number Sequence Position in envelope Predicted MCH-I allele
1 VMAQDKPTVDIELVT 33-47 A2
2 TWVDVVLEHGGCVTV 19-33 B44
3 CLALGGVMIFLSTAV 484-498 A2
3 CLALGGVMIFLSTAV 484-498 A2
4 GWGNGCGLFGKGSLV 100-114 A2
4 GWGNGCGLFGKGSLV 100-114 A24
5 SIQPENLEYRIMLSV 129-143 B44
5 SIQPENLEYRIMLSV 129-143 B44
6 RLKGVSYSLCTAAFTF 295-310 A2
6 RLKGVSYSLCTAAFTF 295-310 A24
6 RLKGVSYSLCTAAFTF 295-310 A24
7 CEPRTGLDFSDLYYL 186-200 B44
7 CEPRTGLDFSDLYYL 186-200 B44
8 TMNNKHWLVHKEWFH 201-215 A2
8 TMNNKHWLVHKEWFH 201-215 A24
9 WLVHKEWFHDIPLPW 207-221 B44
9 WLVHKEWFHDIPLPW 207-221 A24
9 WLVHKEWFHDIPLPW 207-221 A24
10 VVVLGSQEGAVHTAL 251-265 B44
11 PVGRLITANPVITES 350-365 A2
12 PFGDSYIVIGVGDKK 377-391 A24
13 ITHHWHRSGSTIGKA 392-406 A24
14 DFGSVGGVFNSLGKG 426-440 A24
15 SLGKGIHQIFGAAFK 436-450 A2
16 MIGYETDEDRAKVEV 151-165 B44
17 RLITANPVITESTEN 353-367 A2
18 PCKIPVQMAVDMQTL 334-348 A2
A VMAQDKPTV 33-41 A2
B QDKPTVDIE 36-44 -
C PTVDIELVT 39-47 -
Predicted epitopes are indicated in bold.
To validate the specificity of the peptides, we performed ELISPOTS with PBMCs obtained from 
10 control patients from an area free of DENV and ZIKV (New York Blood Bank) and stimulated 
donor cells with each peptide individually. Stimulation with peptide number 16 resulted in IFNγ 
production above background in 7 out of the 10 donors tested, suggesting that this peptide is 
cross-reactive with a common antigen. Therefore, we excluded peptide 16 from further analysis. 
No other peptides induced IFNγ production above background levels in the control PBMCs. 
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Next, we performed ELISPOTS with PBMCs obtained from 7 Brazilian patients with a previous 
ZIKV infection (Table 3). The patients denoted ZIKV 533, 801, 1302, and 2000 did not show IFNγ 
production above background for all peptides tested (Figure 2). Patient 3016 responded to pep-
tide 11 only (2-fold over the background), and 802 and 1310 had a weak IFNγ response against 
many peptides including 1, 3, and 11 (less than 2-fold over the background, Figure 2 and Supple-
mentary Figures 1, 2, and 3). 
Table 3. Patient Demographics
*Informed by the patient/participant, except for DENV-TV003 vaccinees (PRNT pre-vaccination was 
negative)  
** Diagnosis based on symptoms 
nd: Not done 
na: Not applicable 
unk: Unknown 
YF: Yellow Fever
Groups
Donor 
ID
Gen-
der
Age
History of 
Dengue* 
Past YF Immu-
nization*
Day after the onset of symptoms 
or DENV-TV003 immunization of 
blood sample collection
Reported symptoms
PCR
Urine Blood
ZIKV
801 F 53 yes (twice) yes 19 Fever, myalgia + nd
802 F 29 no yes 19 Myalgia + nd
533 F 56 yes yes 159 Myalgia, abdominal pain + -
1302 M 35 no yes 109
Myalgia, nausea, abdominal 
pain
+ nd
1310 F 32 no no 12
Fever, myalgia, retro orbital 
pain
nd +
2000 ** F 37 no yes 15 Fever, myalgia, skin rash - -
3016 F 50 no unk 16
Pruriginous skin rash, con-
juctivitis, myalgia
+ +
DENV
1007 F 38 no unk 90  Mild skin rash na na
1009 M 32 no unk 90  Mild skin rash na na
1011 F 56 no unk 90 none na na
1016 M 47 no unk 90 none na na
1017 F 56 no unk 90 none na na
1020 F 45 no unk 90  Mild skin rash na na
1021 F 50 no unk 90 none na na
1038 F 35 no unk 90  Mild skin rash na na
1040 F 48 no unk 90  Mild skin rash na na
1049 F 37 no yes 90  Mild skin rash na na
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Figure 2. Identification of ZIKV Epitope. PBMCs from ZIKV-infected subjects were stimulated with 
peptides 1-18 and IFNγ production was evaluated by ELISPOT. The dashed line represents the background 
level of IFNγ in the absence of stimulation multiplied by 2.
We then stimulated PBMCs obtained from 9 Brazilian individuals, previously vaccinated against 
DENV (Tables 3 and 4), with the ZIKV peptides. These DENV-vaccinated individuals received 
the live, attenuated tetravalent vaccine TV003 [31] as part of a phase 2 clinical trial (clinicaltrials.
gov identifier: NCT01696422) currently being conducted in Brazil, and samples were collected 
before ZIKV arrived in São Paulo. Two of the DENV-vaccinated participants (1007 and 1016) did 
not respond to any of the peptides, and 2 responded only to peptide 11 (1009 and 1017) (Figure 3 
and Supplementary Figures 1 and 2). The remaining 5 DENV-vaccinated individuals (1021, 1020, 
1038, 1040, and 1049) responded to at least 2 of the peptides, albeit some of the responses were 
modest (Figure 3 and Supplementary Figures 1 and 3). Overall, peptides 1, 3, and 11 induced a 
response in both ZIKV-infected and DENV-vaccinated individuals, with the strongest responses 
observed for peptides 1 and 11. The different time points at which samples were collected made 
a direct comparison of the magnitude of the IFNγ response between the ZIKV-infected patients 
and the DENV-vaccinated individuals impossible. Some had high background IFNγ levels that 
could have masked weak antigen-specific responses. However, we could still detect antigen-spe-
cific responses in those participants (ie, ZIKV 3016, DENV 1009, and DENV 1017).
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Table 4: HLA-I alleles of DENV-vaccinated participants.
Samples HLA A HLA A HLA B HLA B HLA C HLA C
DENV 1007 A*03:ABWKR A*29:ABWMY B*44:ABYSJ B*58:ACBCJ C*03:ACPXG C*16:ACPWC
DENV 1009 A*24:ACPYT A*24:HYYJ B*40:ACKGC B*51:ABUUP C*03:ABUVB C*14:ABUWF
DENV 1011 A*02:ZRVU A*02:ZRVU B*41:ZRNP B*50:ABWUY C*06:ABWZK C*07:ABWZU
DENV 1016 A*02:ABWJM A*24:ACAEP B*44:ABYRU B*44:ABWUJ C*05:ACBEA C*16:ABZVM
DENV 1017 A*29:ABWMX A*31:ABWNG B*39:VZGY B*44:ACBUY C*07:ABXAG C*16:ABXBJ
DENV 1020 A*02:ABVHV A*23:ZKEV B*27:ACMMT B*58:ACJEC C*05:ABZTT C*07:ABZUE
DENV 1021 A*29:ACDMP A*29:ACDMP B*14:ABYJF B*44:ABZPN C*08:ACAMF C*16:ABZVM
DENV 1038 A*02:ABZCH A*33:ABYFZ B*15:KPAE B*44:ACNAV C*03:ACFEZ C*14:ACFHD
DENV 1040 A*02:ABUKX A*29:ABUKV B*38:WDAZ B*44:ABZAB C*12:ABZAC C*16:ABZAD
DENV 1049 A*02:ABVRS A*26:ABVSS B*14:ABWRH B*51:ABWXE C*08:ACBFG C*15:ACBGC
Figure 3. Identification of DENV-ZIKV Cross-reactive Peptides. PBMCs from DENV-vaccinated sub-
jects were stimulated with peptides 1-18 and IFNγ production was evaluated by ELISPOT. The dashed line 
represents the background level of IFNγ in the absence of stimulation multiplied by 2.
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Finally, we selected peptide 1 to use for fine epitope mapping with PBMCs from participants 
DENV 1038 and DENV 1049, who were chosen based on their strong responses to this peptide 
and because they carry the predicted HLA-I allele for this peptide (HLA-A2, Tables 2 and 4). 
The PBMCs were stimulated with the complete 15-mer peptide or 3 overlapping 9-mer peptides 
corresponding to the first 9 (A), the middle 9 (B), and the last 9 (C) amino acids of peptide 1 
(Table 2). Peptide A was predicted to bind strongly to HLA-A2, and both DENV 1038 and DENV 
1049 carried this allele. Stimulation with the complete peptide resulted in an IFNγ response, but 
surprisingly, stimulation with peptide A did not induce a response (Figure 4 A). Similarly, stimu-
lation with peptides B and C resulted in no or weak IFNγ responses. The requirement for the full 
15-mer peptide suggests that peptide 1 might be presented by HLA-II. To test this, flow cytome-
try was used to determine if peptide 1 generated a CD4+ or CD8+ T-cell response. The PBMCs 
from participants DENV 1038 and DENV 1049 were labeled with CellTrace Violet before being 
cultured for 6 days in the presence or absence of the peptide. The cells were then re-stimulated 
with the peptide, and antigen-specific cells were identified as CellTrace Violet low and IFNγ+. 
Background IFNγ production (CellTrace Violet high, IFNγ+) did not change after peptide stimu-
lation, but an antigen- specific response was identified for both donors (Figure 4 B). The majority 
of the CellTrace Violet low and IFNγ+ cells were CD4+ T cells for both DENV-vaccinated partici-
pants. We then determined the HLA-II alleles carried by DENV 1038 (HLA-DRB1*04 and HLA-
DRB1*13) and DENV 1049 (HLA-DRB1*03 and HLA-DRB1*04) and used the IEDB analysis 
resource consensus tool [24, 25] to evaluate if peptide 1 could be presented by these alleles. We 
found that peptide 1 is predicted to be a strong binder for HLA-DRB1*03 (percentile rank 3.22) 
and HLA-DRB1*13 (percentile rank 2.40). While we only observed a CD4+ T-cell response for 
subjects DENV 1038 and DENV 1049, it is still possible that other DENV-vaccinated individu-
als carrying HLA-A2 will generate a CD8+ T-cell response against peptide 1. Because of sample 
limitations, we could not perform fine epitope mapping for the ZIKV-infected patients. Further 
studies will be needed to determine the HLA restriction of the other ZIKV epitopes identified.
T-cell cross-reactivity could have a positive or negative impact on ZIKV infection. In fact, many 
ZIKV-infected people will have had a prior DENV infection or been exposed to other flavivirus-
es, such as those receiving the YF vaccine. Prior infections or vaccinations sometimes negative-
ly impact the response to a subsequent infection, a phenomenon that has been called “original 
antigenic sin (OAS)”. This OAS occurs in serial infections with pathogens that share cross-reactive 
antigens. For example, preformed memory T cells, which cross-react with low avidity to epitopes 
presented in subsequent infections, could dampen the response of high-avidity T cells [32-34]. 
Alternatively, cross-reactive T cells might have a protective effect. This is supported by evidence 
showing that flavivirus-immune individuals have better protection than flavivirus-naive subjects 
following DENV vaccination [35]; in addition, T-cell cross-reactivity is further complicated by 
the highly polymorphic nature of HLA molecules. In other words, prior DENV infection or vacci-
nation could impact the ZIKV T-cell response. In mice, ZIKV/DENV cross-reactive CD8+ T cells 
induced by DENV infection were found to contribute to protection against ZIKV infection [22].
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Figure 4. Fine Mapping of Peptide 1. IFNγ spots per million PBMCs after stimulation with peptides 1, A, 
B, and C for DENV 1038 and 1049. The dashed line represents the background level of IFNγ in the absence 
of stimulation multiplied by 2 (A). CellTrace Violet labeled PBMCs were stimulated for 6 days with pep-
tide 1 in the presence of IL-2 (20 U/ml) before re-stimulation with peptide 1 for 12 hours in the presence 
of monensin. As a negative control, PBMCs were cultured with IL-2 in absence of peptide stimulation. 
Cells were then stained for CD3, CD4, CD8, and IFNγ. Representative flow plots (B).
In this study, we have identified ZIKV T-cell epitopes and demonstrated that vaccination against 
DENV induces a T-cell response against ZIKV. Given the similarity in the T-cell response be-
tween DENV natural infection and vaccination [36], it is likely that natural DENV infection 
can also generate a T-cell response against ZIKV. More research is needed to determine if this 
cross-reactive immune response is protective or contributory to ZIKV pathology. In particular, 
the ZIKV CD4+ T-cell response induced by DENV vaccination and identified in this study could 
contribute to the appearance of cross-reactive antibodies mediating ADE. A better understanding 
of the interactions between ZIKV and DENV immunity, whether induced by vaccination or by 
natural infection, will be critical to obtain safe and efficient vaccines. 
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SUPPLEMENTARY MATERIALS
Supplementary Figure 1. IFNgamma ELISPOT results for unstimulated PBMCs (top row) or stimulated 
with peptide 1 (lower row).
Supplementary Figure 2. IFNgamma ELISPOT results for unstimulated PBMCs (top row) or stimulated 
with peptide 3 (lower row).
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Supplementary Figure 3. IFNgamma ELISPOT results for unstimulated PBMCs (top row) or stimulated 
with peptide 11 (lower row).
